Clinical Trial Results: Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration [NA]

View source ↗

Summary

Completed clinical trial evaluating Dermabond to mitigate spinal cord stimulation lead migration in chronic pain patients; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pain

Drugs mentioned

• Dermabond (2-octyl cyanoacrylate)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Chronic Pain | NA | Status: COMPLETED | Results posted: 2026-06-09